Torna al Registre Simple

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorBauer, Todd
dc.contributor.authorShaw, Alice Tsang
dc.contributor.authorJohnson, Melissa L.
dc.contributor.authorNavarro Mendivil, Alejandro
dc.contributor.authorGainor, Justin F.
dc.contributor.authorThurm, Holger
dc.contributor.authorFelip Font, Enriqueta
dc.date.accessioned2021-10-26T07:11:19Z
dc.date.available2021-10-26T07:11:19Z
dc.date.issued2020-02
dc.identifier.citationBauer TM, Shaw AT, Johnson ML, Navarro A, Gainor JF, Thurm H, et al. Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer. Target Oncol. 2020 Feb;15:55–65.
dc.identifier.issn1776-260X
dc.identifier.urihttp://hdl.handle.net/11351/6462
dc.descriptionLorlatinib; Càncer de pulmó
dc.description.sponsorshipThis study was sponsored by Pfizer Inc.
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofseriesTargeted Oncology;15
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.sourceScientia
dc.subjectPulmons - Càncer - Tractament
dc.subjectAvaluació de resultats (Assistència sanitària)
dc.subject.meshCarcinoma, Non-Small-Cell Lung
dc.subject.mesh/drug therapy
dc.subject.meshDisease Progression
dc.titleBrain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1007/s11523-020-00702-4
dc.subject.decscarcinoma de pulmón de células no pequeñas
dc.subject.decs/farmacoterapia
dc.subject.decsprogresión de la enfermedad
dc.relation.publishversionhttps://doi.org/10.1007/s11523-020-00702-4
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Bauer TM, Johnson ML] Sarah Cannon Cancer Research Institute/Tennessee Oncology, PLLC, 250 25th Ave N, Nashville, TN 37203, USA. [Shaw AT, Gainor JF] Massachusetts General Hospital, 55 Fruit St, Boston, MA 02114, USA. [Navarro A, Felip E] Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Thurm H] Pfzer Oncology, 10777 Science Center Dr, La Jolla, CA, USA
dc.identifier.pmid32060867
dc.identifier.wos000514800300007
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Fitxers en aquest element

Thumbnail
Thumbnail

Aquest element apareix en la col·lecció o col·leccions següent(s)

Torna al Registre Simple